Azura Ophthalmics
PrivateLast Round
Series C
Oct 22, 2020
Total Funding Raised
$37.2M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Azura Ophthalmics is a clinical-stage biopharmaceutical company developing a new class of Ophthalmic Keratolytics for the treatment of Meibomian gland dysfunction (MGD) and other ocular surface diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Azura Ophthalmics Comparables
Compare Azura Ophthalmics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novaliq | 84% | |
| Stuart Therapeutics, Inc. | 77% | |
| Aldeyra Therapeutics | 76% |
Azura Ophthalmics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 22, 2020 | ||||
| Series B | Oct 10, 2017 | ||||
| Series A | Mar 11, 2014 |
Key People
Founding team and executive leadership
Azura Ophthalmics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ganot Capital | Series B, Series A, Series C |
| OrbiMed | Series B, Series C |
| TPG Biotech | Series B, Series C |
| Elron Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 5304% MoM, from 25 to 1.4K.
- May 1, 2025
Monthly visitors increased 77% MoM.
Azura Ophthalmics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Azura Ophthalmics's valuation, stock price, and market status.
Is Azura Ophthalmics a public or private company?
Azura Ophthalmics is a private company.
What is the current stock price of Azura Ophthalmics?
Azura Ophthalmics is a private company with no public stock price. No recent secondary market data is available.
How much is Azura Ophthalmics worth (valuation)?
Valuation information for Azura Ophthalmics is not publicly available.
Can I buy Azura Ophthalmics stock?
Azura Ophthalmics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Azura Ophthalmics's last funding round?
Azura Ophthalmics's most recent funding round was Series C on October 22, 2020.
Who are the main investors in Azura Ophthalmics?
Key investors in Azura Ophthalmics include Ganot Capital, OrbiMed, TPG Biotech.
Will Azura Ophthalmics IPO soon?
No public IPO plans have been announced for Azura Ophthalmics.
How can I track Azura Ophthalmics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Azura Ophthalmics's secondary market activity and sign up for updates.